Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $7.0 billion.

  • Takeda Pharmaceutical's Cash & Current Investments rose 2459.02% to $7.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.0 billion, marking a year-over-year increase of 2459.02%. This contributed to the annual value of $4.8 billion for FY2025, which is 4739.81% up from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Cash & Current Investments of $7.0 billion as of Q4 2025, which was up 2459.02% from $7.1 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Cash & Current Investments ranged from a high of $11.2 billion in Q2 2021 and a low of $3.2 billion during Q1 2024
  • Over the past 5 years, Takeda Pharmaceutical's median Cash & Current Investments value was $6.5 billion (recorded in 2023), while the average stood at $7.0 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Cash & Current Investments soared by 5786.42% in 2021, and later crashed by 4440.37% in 2023.
  • Takeda Pharmaceutical's Cash & Current Investments (Quarter) stood at $10.5 billion in 2021, then fell by 24.37% to $8.0 billion in 2022, then crashed by 31.75% to $5.4 billion in 2023, then increased by 3.55% to $5.6 billion in 2024, then increased by 24.59% to $7.0 billion in 2025.
  • Its last three reported values are $7.0 billion in Q4 2025, $7.1 billion for Q3 2025, and $5.0 billion during Q2 2025.